The dual-incretin molecule, read at the chemistry: how one engineered 39-residue peptide moves blood pressure, lipids and weight in the trial record.
Tirzepatide Chemical

Tirzepatide References — Tirzepatide Chemical

Full reference list

All citations used across Tirzepatide Chemical, with DOIs and PubMed URLs where available.

  1. Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. ↗
  2. Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. ↗
  3. Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. ↗
  4. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. ↗
  5. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;392(14):1364-1376. ↗
  6. Zeng Q, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1214334. ↗
  7. Farzam K, Patel P. Tirzepatide. StatPearls [Internet]. NCBI Bookshelf. 2024. ↗
  8. Kaplan LM, et al. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes. Cardiovasc Diabetol. 2023;22(1):83. ↗
  9. Eli Lilly and Company. A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT). ClinicalTrials.gov. 2020. ↗
  10. Kanbay M, et al. Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023;25(12):3766-3774. ↗
  11. Vadher K, et al. Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes. Diabetes Care. 2024;47(5):868-876. ↗
  12. Loomba R, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):296-306. ↗
  13. Nissen SE, et al. Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial. JAMA Cardiol. 2026. ↗
  14. Krüger N, et al. Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice. Nat Med. 2026. ↗
  15. Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. ↗
  16. Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. ↗
  17. Mishra R, et al. Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis. Cureus. 2023;15(10):e46091. ↗
  18. Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. ↗
  19. U.S. Food and Drug Administration. Tirzepatide injection prescribing information (FDA label, type 2 diabetes). 2022. ↗
  20. Zhang Z, et al. Tirzepatide safety in type 2 diabetes: a disproportionality analysis of the FAERS database. Endocr Connect. 2025. ↗
  21. Gong J, et al. Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide. J Diabetes Investig. 2025. ↗
  22. Nassar M, et al. Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide. Diabetes Metab Syndr. 2024. ↗
  23. Jalleh RJ, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists — Relevance to the Peri-Procedural Setting. J Clin Endocrinol Metab. 2024. ↗
  24. Look M, et al. Body composition changes during weight reduction with tirzepatide in type 2 diabetes and obesity. Diabetes Obes Metab. 2025. ↗
  25. Urva S, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2020;22(10):1886-1891. ↗
  26. Kunutsor SK, et al. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Review. Drugs. 2026. ↗
  27. Locatelli JC, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care. 2024;47(3):e20-e22. ↗
  28. Horn DB, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal. JAMA Intern Med. 2026. ↗
  29. Qazi S, et al. Comparative Efficacy and Safety of Tirzepatide Versus Dulaglutide in Patients with Type 2 Diabetes or Obesity. Healthcare (Basel). 2026;14(7):850. ↗
  30. et al. Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. Cureus. 2025. ↗
  31. U.S. Food and Drug Administration. FDA approval for chronic weight management (tirzepatide) — press announcement. 2023. ↗
  32. Campbell JE, et al. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss — chemistry, physiology, and clinical applications. Cell Metab. 2023;38(1):12-28. ↗
  33. Rasouli N, et al. Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis. Diabetes Ther. 2025. ↗
  34. Galindo RJ, et al. Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials. JAMA Netw Open. 2026. ↗
  35. Yin Y, et al. Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO). Med. 2026. ↗